Nave blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity

Immunology and Cell Biology

Volumn 89, Issue 1, 2011, Pages 7-13

  Slaney, Clare Y ^a   Toker, Aras ^a   Flamme, Anne La ^b   Bäckström, B Thomas ^a,c   Harper, Jacquie L ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c NOVO NORDISK A S   (Denmark)

Author keywords

autoimmunity; blood monocytes; EAE; nitric oxide; T cell suppression

Indexed keywords

CD11B ANTIGEN; NITRIC OXIDE; MEMBRANE ANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CELL CONTACT; HOMEOSTASIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CELL COMMUNICATION; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, SURFACE; AUTOIMMUNITY; CELL COMMUNICATION; CELL PROLIFERATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOCYTES; NITRIC OXIDE; T-LYMPHOCYTES;

EID: 78651079511     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.110     Document Type: Article

References (37)

1. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004; 76: 509-513.
2. Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR et al. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med 2001; 194: 1123-1140.
3. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461.
4. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123: 39-49.
5. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
6. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta1. J Immunol 2009; 182: 240-249.
7. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
8. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006; 66: 6807-6815.
9. Gabrilovich DI, Bronte V, Chen S-H, Colombo MP, Ochoa A, Ostrand-Rosenberg S et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 425.
10. Krystal G, Sly L, Antignano F, Ho V, Ruschmann J, Hamilton M. Re: the terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 3986.
11. Yang R, Roden RBS. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 426.
12. Lagasse E, Weissman IL. Flow cytometric identification of murine neutrophils and monocytes. J Immunol Methods 1996; 197: 139-150.
13. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008; 83: 64-70.
14. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
15. Radvanyi LG, Mills GB, Miller RG. Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J Immunol 1993; 150: 5704-5715.
16. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK et al. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007; 179: 5228-5237.
17. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165: 779-785.
18. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739-1742.
19. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol 1990; 144: 548-556.
20. Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol 1989; 143: 15-22.
21. Gajewski TF, Goldwasser E, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor. J Immunol 1988; 141: 2635-2642.
22. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988; 140: 4245-4252.
23. McNeill A, Spittle E, Backstrom BT. Partial depletion of CD69 low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61. Scand J Immunol 2007; 65: 63-69.
24. Zhou R, He PL, Ren YX, Wang WH, Zhou RY, Wan H et al. Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice. Cancer Sci 2007; 98: 882-889.
25. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-999.
26. Brys L, Beschin A, Raes G, Ghassabeh GH, Noel W, Brandt J et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 2005; 174: 6095-6104.
27. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174: 636-645.
28. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
29. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67: 10019-10026.
30. Rossner S, Voigtlander C, Wiethe C, Hanig J, Seifarth C, Lutz MB. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005; 35: 3533-3544.
31. Moore SC, Shaw MA, Soderberg LS. Transforming growth factor-beta is the major mediator of natural suppressor cells derived from normal bone marrow. J Leukoc Biol 1992; 52: 596-601.
32. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008; 180: 335-349.
33. Honey K. Reduction in regulation. Nat Rev Immunol 2004; 4: 322.
34. +CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979.
35. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-341.
36. Petersen TR, Gulland S, Bettelli E, Kuchroo V, Palmer E, Backstrom BT. A chimeric T cell receptor with super-signaling properties. Int Immunol 2004; 16: 889-894.
37. +CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 2006; 12: 267-274